Pelthos Therapeutics Inc. Common Stock (PTHS)
Stock · AMEX · Health Care
$20.29as of 10/16/2026
Price chart
Active signals
PTHS Signal Track Record
How signals performed across all stocks →What PTHS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 12 | -1.6% | 42% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 11 | +2.6% | 64% | August 17, 2026 |
| Bollinger Band Breakout | 10 | +5.1% | 60% | August 6, 2026 |
| Bollinger Band Breakdown | 8 | +10.2% | 63% | September 15, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since December 2, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PTHS
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult an…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 92
- Website
- ir.pelthos.com/
Fundamentals
- 1-day range
- $19.91$20.57
- Market cap
- $102.36M
- P/E (trailing)
- —
- P/E (forward)
- -3.56
- EPS (trailing)
- $-21.82
- Dividend yield
- —
- Beta
- 3.13
- Avg. volume
- 61.4K
How Pelthos Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Pelthos Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PTHSPelthos Therapeutics Inc. Common Stock$20.15▼ 0.54%Market cap $102.36MP/E —$18.19$37.5
- CGTXCognition Therapeutics Inc. Common Stock$0.73▼ 0.41%Market cap $101.13MP/E —$0.5501$2
- KLRSKalaris Therapeutics Inc. Common Stock$2▼ 8.68%Market cap $99.69MP/E —$2.35$11.88
- BDTXBlack Diamond Therapeutics Inc. Common Stock$1.72▼ 1.15%Market cap $110.02MP/E —$1.6$4.94
- ENGNenGene Therapeutics Inc. Common Stock$1.67▼ 2.34%Market cap $120.58MP/E —$1.4$12.25
- CRDFCardiff Oncology Inc. Common Stock$0.9▼ 7.22%Market cap $74.71MP/E —$0.7566$3.31
- ATRAAtara Biotherapeutics Inc. Common Stock$9.18▼ 4.87%Market cap $74.33MP/E —$3.92$19.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics Inc. Common Stock | $102.36M | — | $20.15 | ▼ 0.54% | $18.19$37.5 |
| CGTX Cognition Therapeutics Inc. Common Stock | $101.13M | — | $0.73 | ▼ 0.41% | $0.5501$2 |
| KLRS Kalaris Therapeutics Inc. Common Stock | $99.69M | — | $2 | ▼ 8.68% | $2.35$11.88 |
| BDTX Black Diamond Therapeutics Inc. Common Stock | $110.02M | — | $1.72 | ▼ 1.15% | $1.6$4.94 |
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.67 | ▼ 2.34% | $1.4$12.25 |
| CRDF Cardiff Oncology Inc. Common Stock | $74.71M | — | $0.9 | ▼ 7.22% | $0.7566$3.31 |
| ATRA Atara Biotherapeutics Inc. Common Stock | $74.33M | — | $9.18 | ▼ 4.87% | $3.92$19.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Friedberg Ezra M · October 2, 2026 · Sale558 @ $20.72
- Matthew Pauls · October 2, 2026 · Sale786 @ $21
- Peter Greenleaf · October 2, 2026 · Sale797 @ $21.17
- Matthew Pauls · July 2, 2026 · Sale692 @ $26
- Peter Greenleaf · July 2, 2026 · Sale85 @ $27.27
- Peter Greenleaf · July 2, 2026 · Sale712 @ $26
- Friedberg Ezra M · July 2, 2026 · Sale24 @ $27.33
- Friedberg Ezra M · July 2, 2026 · Sale534 @ $26.03
- Matthew Pauls · July 2, 2026 · Sale94 @ $27.36
- Davis Todd C · June 11, 2026 · Buy503 @ $28.73
- Davis Todd C · June 11, 2026 · Buy35.4K @ $27.8
- Knuettel Francis II · May 22, 2026 · Sale1.5K @ $26.84
- Knuettel Francis II · May 22, 2026 · Disposition13.9K
- Knuettel Francis II · May 22, 2026 · Disposition42.5K
- Knuettel Francis II · May 22, 2026 · Grant59.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 902.5K
- Total value held
- $18.96M
- Institutional holders
- 16
- Unknown296.3K
- Unknown256.6K
- Unknown93.1K
- Unknown81.9K
- Unknown50.4K
- Unknown41.4K
- Unknown24.8K
- Unknown21.1K
- Unknown15.3K
- Unknown12.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Pelthos Expands Coverage for ZELSUVMI Topical Gel
Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.
Pelthos Expands Coverage for ZELSUVMI Topical Gel. Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.